BRD4: An emerging prospective therapeutic target in glioma
Despite advances in treatment, the prognosis for glioma patients remains poor. Bromodomain-containing protein 4 (BRD4), a member of the bromodomain and extraterminal (BET) protein family, plays an important role in controlling oncogene expression and genome stability. In recent years, numerous BRD4...
Main Authors: | Hua Yang, Li Wei, Yang Xun, Anping Yang, Hua You |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-06-01
|
Series: | Molecular Therapy: Oncolytics |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2372770521000371 |
Similar Items
-
Targeting BRD9 for Cancer Treatment: A New Strategy
by: Zhu X, et al.
Published: (2020-12-01) -
Targeting mechanotransduction at the transcriptional level: YAP and BRD4 are novel therapeutic targets for the reversal of liver fibrosis
by: Altynbek Zhubanchaliyev, et al.
Published: (2016-12-01) -
Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function
by: Adam P. Cribbs, et al.
Published: (2021-02-01) -
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
by: Rosemarie Tremblay-LeMay, et al.
Published: (2018-03-01) -
A Bromodomain-Containing Protein 4 (BRD4) Inhibitor Suppresses Angiogenesis by Regulating AP-1 Expression
by: Zijun Zhou, et al.
Published: (2020-07-01)